Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* The subject's written informed consent must be obtained prior to inclusion.~* Subjects age 40 to 70 years.~* Part B only: Subjects willing to undergoing a screening colonoscopy, where the subject:~  1. is between 40 and 70 years of age and has a known personal or familial risk of colon neoplasia,or~ 2. is aged 55 to 70.~* Part A: Subjects need to be without any history of clinically significant gastrointestinal symptoms by clinical judgement and without the presence of acute abdominal discomfort or symptoms.~* Females of child bearing potential must be surgically sterile, post- menopausal, practicing true sexual abstinence or using an acceptable form of effective contraception throughout the study from the following list: contraceptive injections, implants, oral contraceptives, intrauterine system (IUS), some intrauterine devices (IUDs), vasectomised partner or barrier method (condom or occlusive cap) with spermicidal foam/gel/film/cream/suppository. Females using oral contraceptives must also use additional contraception. Hormonal and IUD methods of contraception must be established for a period of 3 months prior to dosing and cannot be changed or altered during the study. All females must have a negative pregnancy test at screening and check-in (unless post-menopausal).~* Willing, able and competent to complete the entire procedure and to comply with study instructions.~* Ferrous sulphate should be stopped at least one week prior to study medication.~Exclusion Criteria:~* Part A only: Subjects undergoing screening colonoscopy.~* Presence of current clinically significant functional gastrointestinal (GI) disorder (e.g. gastric emptying disorder, chronic constipation, irritable bowel syndrome \[IBS\]).~* Regular use of laxatives or colon motility altering drugs in the last month.~* Donation or loss of 500 mL or more of blood within 8 weeks prior to the first dose of investigational drug.~* Any history or current presence of ileus, gastrointestinal (GI) obstruction or perforation , GI tract cancer, inflammatory bowel disease (IBD) or colonic resection.~* Known glucose-6-phosphatase dehydrogenase deficiency.~* Known phenylketonuria.~* History or evidence of any clinical significant cardiovascular or neurological disease, cardiac, renal or hepatic insufficiency.~* Known hypersensitivity to polyethylene glycols and/or ascorbic acid.~* History or evidence of any clinically relevant electrocardiogram (ECG) abnormalities and/or uncontrolled hypertension.~* Evidence of dehydration.~* Any evidence for clinically significant abnormal sodium or potassium levels or other clinically significant plasma electrolyte disturbances.~* Females who are not post-menopausal with a positive pregnancy test. Females not using reliable methods of birth control if not post-menopausal.~* Clinically relevant findings on physical examination based on the Investigator's judgement.~* Clinically relevant deviations of laboratory parameters from reference ranges at screening or check-in evaluation.~* Positive serology for chronic viral hepatitis or human immunodeficiency virus (HIV) at screening.~* History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or check-in evaluations.~* Subjects who are unwilling to comply with the provisions of the study protocol.~* Concurrent participation in an investigational drug study or participation within 3 months of study entry.~* Subject has a condition or is in a situation, which in the Investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly.~* Previous participation in the study.~* Persons who are ordered to live in an institution on court or authority order

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Part A, arm 1 (Type: EXPERIMENTAL): Evening dose of TF048. Morning dose of TF043
- Part A, arm 2 (Type: EXPERIMENTAL): Evening dose of TF043. Morning dose of TF048
- Part A, arm 3 (Type: EXPERIMENTAL): Evening dose of TF047. Morning dose of TF043
- Part A, arm 4 (Type: ACTIVE_COMPARATOR): MOVIPREP (Both evening and morning dose)
- Part B, arm 1 (Type: EXPERIMENTAL): IMP selected based on the optimal dosing sequence and volume identified from Part A
- Part B, arm 2 (Type: EXPERIMENTAL): IMP as used in Part B, arm 1, with a differing amount of additional clear fluid being consumed
- Part B, arm 3 (Type: ACTIVE_COMPARATOR): IMP as used in Part B, arm 1, except for a reduced amount of ascorbate
- Part B, arm 4 (Type: EXPERIMENTAL): MOVIPREP used in both evening and morning dose

Based on this trial design, predict the completion outcome and termination type (if applicable).